Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 17, 2023

BUY
$26.28 - $33.92 $10,722 - $13,839
408 Added 18.75%
2,584 $72,000
Q3 2022

Oct 07, 2022

BUY
$25.97 - $38.53 $7,842 - $11,636
302 Added 16.12%
2,176 $67,000
Q2 2022

Jul 20, 2022

BUY
$20.88 - $35.19 $28,856 - $48,632
1,382 Added 280.89%
1,874 $55,000
Q1 2022

Apr 26, 2022

BUY
$29.0 - $47.27 $14,268 - $23,256
492 New
492 $16,000
Q2 2021

Jul 30, 2021

SELL
$50.3 - $78.44 $6,287 - $9,805
-125 Closed
0 $0
Q1 2021

Apr 20, 2021

SELL
$53.8 - $81.53 $20,444 - $30,981
-380 Reduced 75.25%
125 $7,000
Q4 2020

Jan 19, 2021

BUY
$36.89 - $93.56 $18,629 - $47,247
505 New
505 $42,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.12B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Exchange Traded Concepts, LLC Portfolio

Follow Exchange Traded Concepts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exchange Traded Concepts, LLC with notifications on news.